An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Bank of England Chief Economist Huw Pill said not too much should be read into a shift in language in November's Monetary ...

Once a drug target is identified, it often takes decades until a chemical compound is developed that can hit the bullseye and ...

Manchester Valley field hockey earned the right to defend its 2A state championship after shutting out C. Milton Wright in ...

On one of the coldest mornings ever in Florida, a young green sea turtle flailed through freezing surf. Too stunned to swim, ...

Risky assets slid, with tech stocks and cryptocurrencies bearing the brunt of the selling, after long-simmering concerns ...

Here’s what clinicians—and everyone else—need to know about treating gambling disorder and protecting those most vulnerable.

Kimberly-Clark plans to acquire Kenvue in a $48.7 billion deal, aiming to boost long-term growth and synergies. Learn more ...

Asian stocks were set to gain Tuesday, tracking advances on Wall Street as Amazon.com Inc.’s $38 billion deal with OpenAI reignited enthusiasm for artificial-intelligence shares.

Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. Learn more about NVO stock here.

Sleepless nights push millions toward pricey gadgets and pills, yet a quiet shift at home is stealing headlines this winter.

Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.